Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion type Assertion NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_head.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion wasGeneratedBy ECO_0000203 NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_provenance.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion wasDerivedFrom befree-20140225 NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_provenance.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion SIO_000772 22672749 NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_provenance.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion evidence source_evidence_literature NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_provenance.
- NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_assertion description "[We analyzed EGFR, KRAS, BRAF, and PIK3CA mutation status with direct sequencing and epidermal growth factor receptor (EGFR) and Phosphatase and tensin homolog (PTEN) expression status with immunohistochemistry in tumor samples of 82 patients with locally advanced rectal cancer who were enrolled in the IRIX trial (preoperative chemoradiation with irinotecan and capecitabine; n=44) or the ERBIRIX trial (preoperative chemoradiation with irinotecan and capecitabine plus cetuximab; n=38).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904115.RARYEv_d0NyDb1mL4V-oBdm64-HZPrUKlOhU-1ClfTJqU130_provenance.